New pancreatic cancer drug approved, but patients face insurance delays

Revolution Medicines' Rasonque was cleared by the FDA, offering a median overall survival benefit that nearly doubles outcomes for metastatic pancreatic cancer. The drug's compassionate-use program shut down upon approval, catching patients like Juan Solano mid-application and forcing them to seek commercial coverage. Insurers, including Aetna, have indicated that adding a newly approved medication to their plans can take months, leaving a critical treatment window uncovered.

Doctors and advocacy groups argue that the lag undermines the drug's life-saving potential and call for policy changes to smooth the transition. Some patients have secured short-term supplies through manufacturer assistance programs, but high monthly costs—about $40,000—remain a barrier. The situation highlights systemic challenges in bringing breakthrough oncology therapies to those who need them most.